US Edition
A double-edged sword: VC timelines are getting longer in biotech
Summary by BioVox
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
A double-edged sword: VC timelines are getting longer in biotech
Biotechnology is an inherently high-risk, high-reward industry. Developing a new therapeutic or diagnostic involves years of preclinical work, clinical trials, and regulatory review – all of which require significant money and time.But the complexity and capital requirements of biotech R&D have been steadily increasing, putting pressure on both entrepreneurs and VC firms. Everyone is having to make investment plans with the shared understanding …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
